Circassia Group PLC
LSE:CIR
Intrinsic Value
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. [ Read More ]
The intrinsic value of one
CIR
stock under the Base Case scenario is
32.81
GBX.
Compared to the current market price of 36.5 GBX,
Circassia Group PLC
is
Overvalued by 10%.
Circassia Group PLC's market capitalization is 153.1m GBX.
CIR stock price is 36.5 GBX.
CIR stock (32.81 GBX) is 10% less than its price (36.5 GBX).
CIR has upside potential of 29% compared to the average analyst price target.
Open Wall St Estimates
CIR's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
CIR's ROE (Return on Equity) for the past 12 months is positive and is equal to 21%.
CIR's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
CIR has positive Operating Income for the last twelve months.
CIR has positive three-year average ROE (Return on Equity): 20%. The company is efficient at transforming stockholders' equity into net income.
CIR generates enough operating income (2m GBP) to cover interest payments on its debt (200k GBP).
CIR has a very low three-year average ROIC (Return on Invested Capital): 1%. The company is not efficient at using invested capital to generate operating income.
CIR has positive Free Cash Flow for the last twelve months.
CIR has positive Net Income for the last twelve months.
CIR has positive Gross Profit for the last twelve months.
CIR's short-term assets (31m GBP) exceed its short-term liabilties (9m GBP).
CIR's D/E (Debt to Equity) is very low and is equal to 0.
CIR's long-term assets (99m GBP) exceed its long-term liabilties (17m GBP).
CIR has negative Net Debt. This means that the company has more cash and short-term investments (19m GBP) than debt (400k GBP).
CIR's Altman Z-Score is very low and is equal to -1.99.
Valuation Backtest
Circassia Group PLC
Run backtest to discover the historical profit from buying and selling
CIR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Circassia Group PLC
Balance Sheet Decomposition
Circassia Group PLC
| Current Assets | 31.4m |
| Cash & Short-Term Investments | 19.4m |
| Receivables | 7.9m |
| Other Current Assets | 4.1m |
| Non-Current Assets | 67.1m |
| PP&E | 1.1m |
| Intangibles | 37.1m |
| Other Non-Current Assets | 28.9m |
| Current Liabilities | 9.2m |
| Accounts Payable | 500k |
| Accrued Liabilities | 7.6m |
| Other Current Liabilities | 1.1m |
| Non-Current Liabilities | 7.4m |
| Long-Term Debt | 400k |
| Other Non-Current Liabilities | 7m |
Earnings Waterfall
Circassia Group PLC
|
Revenue
|
31.3m
GBP
|
|
Cost of Revenue
|
-9.1m
GBP
|
|
Gross Profit
|
22.2m
GBP
|
|
Operating Expenses
|
-20.4m
GBP
|
|
Operating Income
|
1.8m
GBP
|
|
Other Expenses
|
14.3m
GBP
|
|
Net Income
|
16.1m
GBP
|
Free Cash Flow Analysis
Circassia Group PLC
CIR Profitability Score
Profitability Due Diligence
Circassia Group PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Circassia Group PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
CIR Solvency Score
Solvency Due Diligence
Circassia Group PLC's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Circassia Group PLC's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CIR Price Targets Summary
Circassia Group PLC
According to Wall Street analysts, the average 1-year price target for
CIR
is 47 GBX
.
Shareholder Return
CIR Price
Circassia Group PLC
| Average Annual Return | 0.96% |
| Standard Deviation of Annual Returns | 55.98% |
| Max Drawdown | -59% |
| Market Capitalization | 153.1m GBX |
| Shares Outstanding | 418 461 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Circassia Group PLC
Country
Industry
Market Cap
Dividend Yield
Description
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one
CIR
stock under the Base Case scenario is
32.81
GBX.
Compared to the current market price of 36.5 GBX,
Circassia Group PLC
is
Overvalued by 10%.
You don't have any saved screeners yet
